For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation.
An interventional, randomised, parallel-group, double-blind, placebo-controlled, multi-centre, multi-national CVOT designed to evaluate the effects of 15 mg ziltivekimab versus placebo (randomised 1:1), both administered s.c. once-monthly and added to standard of care, on CV outcomes in participants with established ASCVD, CKD and systemic inflammation.
DiagnosisASCVD, CKD and systemic inflammation.
ASCVD, CKD and systemic inflammation.
- ziltivekimab 15 mg/mL single-use pre-filled syringe (1 mL)
- placebo single-use pre-filled syringe (1 mL)
For more information, visit clinicaltrials.gov.